Array BioPharma Inc. (ARRY) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Array BioPharma, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript

  Question-and-Answer Session Operator Thank you. Operator instructions Our first question today is from Ted Tenthoff from Piper Jaffray. Ted Tenthoff – Piper Jaffray Great, thank you very much for taking the time to run through such a thorough update on the company. There's a lot going...

  Earnings calls 2008-09-02

  Tags: Array BioPharma Inc.

• Array BioPharma, Inc., Q3 Earnings Call Transcript

  Question-and-Answer Session Operator Thank you sir. Operator instructions We will move to our first question from Richard Smith, JP Morgan. Richard Smith, Ph.D. – JP Morgan Yes. Good morning. Just a couple quick questions. One on the timing of this financing. Is...

  Earnings calls 2008-05-06

  Tags: Array BioPharma Inc.

• Array BioPharma Inc. Q2 2008 Earnings Call Transcript.

  Question-and-Answer SessionOperator Operator Instruction. We will go first to Richard Smith-JP Morgan. Richard Smith Inaudible Unidentified Company Representative Richard, can you speak up please. Richard Smith Can you hear me now? Unidentified Company Representative Yes, that's better. Richard Smith Okay. Sorry...

  Earnings calls 2008-02-05

  Tags: Array BioPharma Inc.

Additional Resources

• Array BioPharma to Present at the William Blair Small-Cap Growth Stock Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the William Blair Small-Cap Growth Stock Conference on October 7 in New York City. The public is welcome to participate in the conference through a webcast on the Array...

  Articles 2008-09-29

• Array BioPharma Presents Positive Preclinical Data on Its Glucokinase Activators in Type 2 Diabetes

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of preclinical data on a novel small molecule glucokinase activator GKA, ARRY-403, a drug for the treatment of Type 2 diabetes. The data showed that ARRY-403 demonstrated potent, highly glucose-blood-level dependent, control of both fasting and non-fasting glucose...

  Articles 2008-09-25

• Array BioPharma to Present at the Thomas Weisel Partners 2008 Healthcare Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Thomas Weisel Partners 2008 Healthcare Conference on September 3 in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website....

  Articles 2008-08-27

• Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2008

  BOULDER, Colo. -- Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the fourth quarter and full year of fiscal 2008. Array reported revenue of $6.1 million for the fourth quarter of fiscal 2008, compared to revenue of $8.0 million for the same period in fiscal 2007....

  Articles 2008-08-11

• Array BioPharma to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Bank of America 2008 Specialty Pharmaceuticals Conference on August 7 in Southampton, New York. The public is welcome to participate in the conference through a webcast on the...

  Articles 2008-07-30

• Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2008 on August 11, 2008

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2008 on Monday, August 11, 2008, and will hold a conference call on Tuesday, August 12, 2008, at 9:00 a.m. eastern time to discuss these results. Robert E. Conway, Chief...

  Articles 2008-07-28

• Array BioPharma to Present at the Collins Stewart 4th Annual Growth Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Collins Stewart 4th Annual Growth Conference on July 8 in New York. The public is welcome to participate in the conference through a webcast on...

  Articles 2008-06-30

• Array BioPharma to Present at the Jefferies 2nd Annual Healthcare Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Jefferies 2nd Annual Healthcare Conference on June 25 in New York. The public is welcome to participate in the conference through a webcast on the...

  Articles 2008-06-16

• Array BioPharma Presents Additional Positive Phase 1 Results in Two Programs at the 2008 Annual European Congress of Rheumatology

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 1 clinical trial evaluating the pharmacokinetic and pharmacodynamic activity of ARRY-162, a novel small molecule MEK inhibitor, at the 2008 Annual European...

  Articles 2008-06-12

• Array BioPharma to Present Clinical Data at the 2008 Annual European Congress of Rheumatology

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on the MEK inhibitor, ARRY-162, and the pan-cytokine inhibitor, ARRY-797, at the 2008 Annual European Congress of Rheumatology in Paris, France. [TABLE OMITTED] About ARRY-162 / Targeting MEK for...

  Articles 2008-06-10

• Array BioPharma to Present at the Citi 2008 Global Healthcare Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Citi 2008 Global Healthcare Conference on May 21 in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website....

  Articles 2008-05-16

• Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244

  BOULDER, Colo. -- Array BioPharma Inc. (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) today announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half of 2008, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be...

  Articles 2008-05-16

• Array BioPharma to Present at the Banc of America Securities Healthcare Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Banc of America Securities Healthcare Conference on May 13 in Las Vegas. The public is welcome to participate in the conference through a webcast on the Array BioPharma...

  Articles 2008-05-08

• Array BioPharma Presents Additional Positive Phase 2 Results in Inflammatory Pain Clinical Trial at the American Pain Society's Annual Scientific Meeting

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Medical Officer, John Yates, M.D., presented additional positive results from a Phase 2 clinical trial evaluating the efficacy of ARRY-797, a novel small molecule pan-cytokine inhibitor, in patients with post-surgical dental pain at the American Pain Society's...

  Articles 2008-05-07

• Array BioPharma to Present at Leerink Swann Conference

  BOULDER, Colo. -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Leerink Swann Conquering Cancer with Novel Therapeutics: Roundtable Conference on May 9 in New York City. The public is welcome to participate in the conference through a webcast...

  Articles 2008-05-05

• Array BioPharma Receives $80 Million Funding Commitment

  BOULDER, Colo. -- Array BioPharma Inc. (NASDAQ:ARRY), today announced that it has received an $80 million funding commitment from Deerfield Management, a leading healthcare investment organization and one of Array's largest shareholders. Together with existing capital, these funds are expected to enable Array to advance six wholly owned small molecule...

  Articles 2008-05-05

• Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2008

  BOULDER, Colo. -- Array BioPharma Inc. (NASDAQ: ARRY) today reported financial results for the third quarter of fiscal 2008. Array reported revenue of $7.7 million for the third quarter of fiscal 2008, compared to revenue of $10.4 million for the same period in fiscal 2007. Array invested $23.8...

  Articles 2008-05-05